Compugen Adds Biotech Veteran Michele Holcomb to Board Amid Clinical Milestones
Event summary
- Michele Holcomb, Ph.D., joins Compugen's board as an independent director effective February 11, 2026.
- Holcomb brings 30+ years of biotech, pharma, and healthcare services experience, including executive roles at Cardinal Health and Teva Pharmaceuticals.
- Compugen highlights its financial strength, multiple first-in-class clinical programs, and two pharma partnerships as strategic context for the appointment.
- Holcomb currently serves on boards of PureTech Health, Kimball Electronics, and Controlant hf.
- Compugen's pipeline includes COM902 (Phase 1), rilvegostomig (Phase 3 via AstraZeneca), COM701 (Phase 1), and GS-0321 (licensed to Gilead).
The big picture
Compugen's appointment of Michele Holcomb reflects its push to strengthen governance as it scales clinical operations. With multiple first-in-class programs and strategic pharma partnerships, the company is positioning itself for potential value creation. Holcomb's background in corporate development and portfolio management could be particularly valuable as Compugen navigates its next phase of growth.
What we're watching
- Strategic Leadership
- How Holcomb's corporate development expertise will shape Compugen's partnership strategy and pipeline optimization.
- Clinical Milestones
- The pace at which Compugen advances its Phase 1 and Phase 3 programs, particularly COM902 and rilvegostomig.
- Governance Impact
- Whether Holcomb's board experience can help navigate Compugen through potential value-creating inflection points.
Our editorial coverage:
Related topics